TOP 30 Biologics 2010

Download

Top 30 Biologics 2010

To improve the quality of future issues, please send us your comments to This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

The present FREE Download contains a compilation of the 2010 sales of mainly recombinant biologic products including antibodies and proteins. The report provides an overview of the blockbuster biologics (TOP 30 Biologics) with sales exceeding US$ 1 bln and 2010 sales for each class of biologics.

TOP 30 Biologics Sales

The sales of the 30 best selling antibodies and proteins in 2010 are listed up, each of them posting more than US$ 1 bln sales in 2010.

Therapeutic Proteins Sales

The report compiles 2010 sales of the major therapeutic proteins per class: erythropoietin, insulin and insulin analogs, coagulation factors, interferon alpha, interferon beta, granulocyte colony-stimulating factor (G-CSF), human growth hormone (hGH), enzyme replacement therapy and follicle stimulating hormone (FSH).

Erythropoietin

2010 sales of epoetin alfa and epoetin beta from Amgen, Johnson & Johnson (J&J), Roche, Chugai and Kirin are presented for their products Aranesp, Procrit, Eprex, Epogen, ESPO, Neorecormon and Epogin.

Insulin & Insulin Analogs

2010 sales of insulin and insulin analog products from Novo Nordisk, Eli Lilly and Sanofi-Aventis are presented for their products Humalog (insulin lispro), Humulin, Lantus (insulin glargine), Levemir and Novolog (insulin analogue detemir and aspart) as well as for Actrapid, Novolin and others.

Coagulation Factors

2010 sales of recombinant coagulation factor products factor VIIa, VIII and IX from Novo Nordisk, Bayer Schering Pharma, CSL, Baxter and Wyeth are presented for their products Novoseven (eptacog alfa), Kogenate FS (octocog), Helixate FS, Advate, Recombinate, Refacto, Benefix (nonacog).

Interferon alpha and beta

2010 sales of recombinant interferon beta and alfa products are presented for Avonex, Rebif, Betaferon / Betaseron from Biogen Idec, Merck Serono and Bayer Schering Pharma as well as for Pegasys, Peg-Intron and Intron A from Roche and Schering-Plough.

Granulocyte Colony-Stimulating Factor (G-CSF)

2010 sales of recombinant G-CSF products are presented for Neulasta (peg-filgrastim), Neupogen (filgrastim), GRAN (filgrastim) and Neutrogin (lenograstim) from Amgen, Kirin and Chugai.

Human Growth Hormone (hGH)

2010 sales of recombinant human growth hormone (somatostatin) products are presented for Genotropin, Norditropin, Humatrope, Nutropin / Protropin and Saizen / Serostim from Pfizer, Novo Nordisk, Eli Lilly, Genentech / Roche / Ipsen and Merck Serono.

Enzyme Replacement Therpay (ERT)

2009 sales of recombinant human enzyme products for treatment of metabolic diseases such as Gaucher’s disease, Fabry disease and Pompé disease are presented for Cerezyme (imiglucerase), Fabrazyme (agalsidase beta), Myozyme (alglucosidase alfa), Aldurazyme (laronidase), Elaprase (idursulfase), Replagal (agalsidase alfa), VPRIV (velaglucerase) and Naglazyme (galsulfase) from Genzyme, Biomarin, Shire and Dainippon Sumitomo.

Follicle Stimulating Hormone (FSH)

2010 sales of recombinant follicle stimulating hormone (FSH) products for treatment of infertility are presented for Gonal-f (follitropin alfa) and Puregon / Follistim (follitropin beta) from Merck Serono and Schering-Plough.

Other Therapeutic Proteins

2010 sales other therapeutic proteins including botulinum toxin products Botox and Dysport/Reloxin, Pulmozyme, InductOs, TNKase, Thyrogen, Xigris, Kineret, Increlex, Kepivance.

Therapeutic Antibodies Sales

The report compiles 2010 sales of therapeutic antibodies per class: cancer antibodies, anti-TNF antibodies, other anti-inflammatory antibodies, ophthalmic and antiviral antibodies as well as other therapeutic antibodies.

Cancer Antibodies

2010 sales of recombinant monoclonal antibody products are presented for Rituxan / MabThera (rituximab), Herceptin (trastuzumab), Avastin (bevacizumab), Erbitux (cetuximab) and Vectibix (panitumumab), Arzerra, Zevalin, XGEVA, Removab from Genentech / Roche, Bristol-Myers Squibb, Merck Serono, Eli Lilly, Fresenius Biotech, GlaxoSmithKline, Spectrum Pharmaceuticals and Amgen.

Anti-TNF Antibodies

2010 sales of recombinant monoclonal antibodies and fusion proteins targeting tumor necrosis factor alpha (TNF) are presented for Enbrel (etanercept), Remicade (infliximab), Humira (adalimumab), Cimzia (certolizumab pegol) and Simponi (golimumab) from Amgen, Wyeth, Takeda Pharmaceuticals, Centocor (J&J), Schering-Plough, Tanabe Seiyaku, Abbott, Eisai and UCB.

Other Anti-Inflammatory Antibodies

2010 sales of recombinant monoclonal antibodies and fusion proteins such as Actemra/RoActemra, Orencia, Tysabri, Xolair, Soliris, Stelara, Ilaris, Arcalyst and Amevive from Roche, Bristol-Myers Squibb, Novartis, Johnson & Johnson, Regeneron Pharmaceuticals, Biogen Idec, Alexion Pharmaceuticals, Astellas Pharma.

Antiviral Antibody

2010 sales of the recombinant humanized antibody Synagis (palivizumab) targeting respiratory syncytial virus (RSV) for prevention of RSV infection in premature infants from MedImmune (AstraZeneca) are presented.

Ophthalmology Antibody

2010 sales of the recombinant humanized antibody fragment Lucentis targeting VEGF for treatment of age-related macular degeneration from Genentech (Roche) and Novartis are presented.